Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Buys Shares of 11,200 Haemonetics Co. (HAE)

Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in Haemonetics Co. (NYSE:HAE) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 11,200 shares of the medical instruments supplier’s stock, valued at approximately $1,121,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Two Sigma Investments LP acquired a new position in shares of Haemonetics during the fourth quarter valued at $4,585,000. Lord Abbett & CO. LLC acquired a new position in shares of Haemonetics during the fourth quarter valued at $20,326,000. Geode Capital Management LLC increased its holdings in shares of Haemonetics by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 628,695 shares of the medical instruments supplier’s stock valued at $62,900,000 after purchasing an additional 27,344 shares during the period. Magnus Financial Group LLC acquired a new position in shares of Haemonetics during the fourth quarter valued at $227,000. Finally, California State Teachers Retirement System increased its holdings in shares of Haemonetics by 2.4% during the fourth quarter. California State Teachers Retirement System now owns 81,407 shares of the medical instruments supplier’s stock valued at $8,145,000 after purchasing an additional 1,899 shares during the period. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

Shares of HAE stock opened at $84.52 on Monday. Haemonetics Co. has a fifty-two week low of $70.86 and a fifty-two week high of $117.56. The stock has a market cap of $4.31 billion, a P/E ratio of 45.20, a PEG ratio of 2.69 and a beta of 0.89. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.04. Haemonetics had a return on equity of 17.05% and a net margin of 4.84%. The business had revenue of $247.36 million during the quarter, compared to analysts’ expectations of $250.12 million. During the same quarter last year, the business posted $0.62 earnings per share. The company’s quarterly revenue was up 5.7% on a year-over-year basis. As a group, sell-side analysts predict that Haemonetics Co. will post 2.33 EPS for the current fiscal year.

In related news, Director Ronald G. Gelbman sold 8,196 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of $86.52, for a total value of $709,117.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michelle L. Basil sold 391 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $83.57, for a total value of $32,675.87. The disclosure for this sale can be found here. Insiders sold a total of 8,703 shares of company stock valued at $751,488 in the last quarter. 1.04% of the stock is currently owned by corporate insiders.

Several research analysts recently weighed in on the company. Zacks Investment Research cut Haemonetics from a “hold” rating to a “sell” rating in a research note on Thursday, January 24th. Barrington Research raised their target price on Haemonetics to $112.00 and gave the company a “positive” rating in a research note on Wednesday, February 6th. Finally, ValuEngine cut Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Haemonetics has an average rating of “Buy” and a consensus target price of $119.75.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2019/03/25/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-buys-shares-of-11200-haemonetics-co-hae.html.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: Investing strategies using the yield curve

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.